Context Therapeutics (CNTX) Insider Trading & Ownership $0.70 0.00 (-0.43%) As of 02:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Context Therapeutics (NASDAQ:CNTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.04%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$107.21KNumber OfInsiders Selling(Last 12 Months)0 Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CNTX Insider Buying and Selling by Quarter Context Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/9/2025Martin A LehrCEOBuy100,000$0.70$70,000.00 6/6/2025Alex C LevitInsiderBuy20,000$0.58$11,600.00 6/6/2025Jennifer Lynn Minai-AzaryCFOBuy40,010$0.64$25,606.40 (Data available from 1/1/2013 forward) CNTX Insider Trading Activity - Frequently Asked Questions Who is on Context Therapeutics' Insider Roster? The list of insiders at Context Therapeutics includes Alex C Levit, Jennifer Lynn Minai-Azary, and Martin A Lehr. Learn more on insiders at CNTX. What percentage of Context Therapeutics stock is owned by insiders? 3.04% of Context Therapeutics stock is owned by insiders. Learn more on CNTX's insider holdings. Which Context Therapeutics insiders have been buying company stock? The following insiders have purchased CNTX shares in the last 24 months: Alex C Levit ($11,600.00), Jennifer Lynn Minai-Azary ($25,606.40), and Martin A Lehr ($70,000.00). How much insider buying is happening at Context Therapeutics? Insiders have purchased a total of 160,010 CNTX shares in the last 24 months for a total of $107,206.40 bought. Context Therapeutics Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Compensation: $674.08k1 recent tradesMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Compensation: $504.14k1 recent tradesMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Compensation: $483.83k1 recent tradesMr. Christopher Beck M.B.A.Senior Vice President of Operations More Insider Trading Tools from MarketBeat Related Companies SGMT Insider Selling NMRA Insider Selling MNPR Insider Selling DBVT Insider Selling DRUG Insider Selling ALLO Insider Selling GALT Insider Selling TKNO Insider Selling ALMS Insider Selling LRMR Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:CNTX) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
